From the Departments of Internal Medicine (Dr Mattei) and Pathology (Drs Meurer and Kulczynski), School of Medicine, the Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute for Basic Health Sciences (Dr Roesler), and the Cancer Research Laboratory, University Hospital Research Center (CPE-HCPA) (Dr Macedo, Roesler, Brunetto, and Schwartsmann), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; the Departments of Urology (Dr Mattei) and Oncology (Mr Cano and Ms Batlle), University of Colorado, Denver; the Pathology Division, Department of Medicine, National Jewish Health, Denver, Colorado (Drs Achcar and Groshong); the National Institutes for Translational Medicine, Porto Alegre, Brazil (Drs Roesler and Schwartsmann); and the Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium (Dr Dal Lago). Dr Mattei is now with Denver Health Hospital, Denver, Colorado.
Arch Pathol Lab Med. 2014 Jan;138(1):98-104. doi: 10.5858/arpa.2012-0679-OA.
Gastrin-releasing peptide receptors (GRPRs) activate mitogen-activated protein kinase signaling pathway primarily through epidermal growth factor receptor activation and are under investigation as a molecular target because they are overexpressed in several solid tumors.
To determine GRPR expression in both non-small cell lung carcinoma and small cell lung carcinoma, comparing results with clinical stages and demographic data.
We analyzed the immunohistochemical expression of GRPR in 200 non-small cell lung carcinoma and 38 small cell lung carcinoma archival cases from 2004 to 2008.
Non-small cell lung carcinoma cases tended to be higher GRPR expressers at a rate of 62.5% (weak, moderate, and strong expression in 41.5%, 13.5%, and 7.5%, respectively), compared with 52.62% in small cell lung carcinoma cases (weak, moderate, and strong expression in 34.21%, 15.78%, and 2.63%, respectively; P = .30). In non-small cell lung carcinoma there was a trend for higher percentages of strong expression in adenocarcinoma cases (10%; P = .67), and in patients with advanced stages (III and IV; 9.43% and 6.9%; P = .01).
To the best of our knowledge, this is the first study to demonstrate GRPR tissue expression in a large population of patients with lung cancer. Although GRPR expression was similar in small cell and non-small cell carcinoma, the expression was more pronounced in an advanced-stage lung cancer, particularly in adenocarcinoma cases, and may represent a potential target for the development of new treatment approaches in this population.
胃泌素释放肽受体（GRPR）通过表皮生长因子受体激活主要激活丝裂原活化蛋白激酶信号通路，作为分子靶点正在研究中，因为它们在几种实体瘤中过度表达。
比较临床分期和人口统计学数据，确定非小细胞肺癌和小细胞肺癌中 GRPR 的表达。
我们分析了 2004 年至 2008 年间 200 例非小细胞肺癌和 38 例小细胞肺癌存档病例中 GRPR 的免疫组织化学表达。
非小细胞肺癌病例的 GRPR 表达率较高，为 62.5%（弱、中、强表达分别为 41.5%、13.5%和 7.5%），而小细胞肺癌病例为 52.62%（弱、中、强表达分别为 34.21%、15.78%和 2.63%；P=.30）。在非小细胞肺癌中，腺癌病例强表达的百分比呈上升趋势（10%；P=.67），且在晚期（III 和 IV 期）患者中也呈上升趋势（9.43%和 6.9%；P=.01）。
据我们所知，这是第一项在大量肺癌患者中证明 GRPR 组织表达的研究。尽管小细胞癌和非小细胞癌中 GRPR 的表达相似，但在晚期肺癌中表达更为明显，尤其是在腺癌病例中，这可能代表该人群开发新治疗方法的潜在靶点。
